The use of hydroxychloroquine in patients with chronic obstructive pulmonary disease (COPD) requires caution due to the medication's potential to exacerbate respiratory symptoms and cause bronchospasm.
Imulast Patients with COPD may be at increased risk of adverse respiratory effects with hydroxychloroquine therapy, particularly if they have underlying airway hyperreactivity or a history of asthma. Healthcare providers should monitor patients closely for respiratory symptoms and consider alternative therapies when appropriate.
